Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiosurgery 6pembrolizumab 4Carboplatin 3atezolizumab 2aldesleukin 2Paclitaxel 2Nivolumab 2Cyclophosphamide 2osimertinib 1durvalumab 1avelumab 1amatuximab 1Vitamin A 1Tobacco Use Cessation Devices 1Thoracic Surgical Procedures 1Taxes 1Radiotherapy 1Radiation Dose Hypofractionation 1RXDX-106 1Proton Therapy 1Pemetrexed 1Optical Fibers 1Oncolytic Virotherapy 1Itraconazole 1Interleukin-2 1Fluorodeoxyglucose F18 1Ethiodized Oil 1Erlotinib Hydrochloride 1Docetaxel 1Dihematoporphyrin Ether 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Non-Small-Cell Lung × DEAE-Dextran × Clear all
NCT06712745 2025-11-10

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung

University of Texas Southwestern Medical Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡